BIOSYNTHETIC SYSTEM THAT PRODUCES IMMUNOGENIC POLYSACCHARIDES IN PROKARYOTIC CELLS

(19)

(11)

EP 2 501 406 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	24.01.2018 Bulletin 2018/04

(45)	Mention of the grant of the patent:
	20.12.2017 Bulletin 2017/51

(21)	Application number: 10831896.5

(22)	Date of filing: 16.11.2010

(51)

International Patent Classification (IPC):

A61K 39/385^(2006.01)
A61K 39/108^(2006.01)

A61K 39/02^(2006.01)
C07K 1/00^(2006.01)

(86)	International application number:
	PCT/US2010/002980

(87)	International publication number:
	WO 2011/062615 (26.05.2011 Gazette 2011/21)

(54)	BIOSYNTHETIC SYSTEM THAT PRODUCES IMMUNOGENIC POLYSACCHARIDES IN PROKARYOTIC CELLS BIOSYNTHETISCHES SYSTEM ZUR HERSTELLUNG IMMUNOGENER POLYSACCHARIDE IN PROKARYOTISCHEN ZELLEN SYSTÈME DE BIOSYNTHÈSE QUI PRODUIT DES POLYSACCHARIDES IMMUNOGÈNES DANS LES CELLULES PROCARYOTES

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

19.11.2009 US 272931 P

(43)	Date of publication of application:
	26.09.2012 Bulletin 2012/39

(73)	Proprietor: GlaxoSmithKline Biologicals S.A.
	1330 Rixensart (BE)

(72)	Inventors:
	WACKER, Michael CH-8103 Unterengstringen (CH) WAECHTER, Charles Lexington, KY 40502 (US)

(74)	Representative: Johnston, Caroline Louise
	GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS Brentford, Middlesex TW8 9GS (GB)

(56)

References cited: :

WO-A2-2006/119987
WO-A2-2009/104074
US-A1- 2004 265 954

WO-A2-2009/089396
US-A1- 2003 023 075

MARIO F FELDMAN ET AL: "Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 102, no. 8, 22 February 2005 (2005-02-22), pages 3016-3021, XP009121034, ISSN: 0027-8424, DOI: 10.1073/PNAS.0500044102 [retrieved on 2005-02-09]
JEFFREY S RUSH ET AL: "A novel epimerase that converts GIcNAc-P-P-undecaprenol to GaINAc-P-P- undecaprenol in Escherichia coli 0157", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 285, no. 3, 18 November 2009 (2009-11-18), pages 1671-1680, XP008159043, ISSN: 0021-9258, DOI: 10.1074/JBC.M109.061630
DMITRIEV ET AL.: 'Somatic antigens of Shigella. The structure of the specific polysaccharide of Shigella newcastle (Sh. flexneri type 6) lipopolysaccharide.' EUR. J. BIOCHEM. vol. 98, no. 1, 1979, pages 309 - 316, XP008159041
RUSH ET AL.: 'A novel epimerase that converts GIcNAc-P-P-undecaprenol to GaINAc-P-P- undecaprenol in Escherichia coli 0157.' J. BIOL. CHEM. vol. 285, no. 3, 18 November 2009, pages 1671 - 1680, XP008159043

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).